A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer

Rustin, G; Vergote, I; Micha, JP; Duska, LR; Reed, N; Bendell, J; Spitz, D; Dark, G; Hoch, U; Tagliaferri, M; Hannah, AL; Garcia, AA

Garcia, AA (reprint author), Louisiana State Univ, 533 Bolivar St, New Orleans, LA 70112 USA.

GYNECOLOGIC ONCOLOGY, 2017; 147 (2): 276

Abstract

Objective. Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索